Abstract
The closeout phase starts with the final follow-up visit of the first participant enrolled and lasts until all the analyses have been completed. It is evident that well before the scheduled end of the trial, there needs to be a fairly detailed plan for this phase if the study is to be completed in an orderly manner. Importantly, one must be prepared to implement or modify this plan prior to the scheduled termination since unexpected trial results, either beneficial or harmful, may require the trial to be stopped early.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shepherd R, Macer JL, Grady D. Planning for closeout – from day one. Contemp Clin Trials 2008;29:136–139.
Pressel SL, Davis BR, Wright Jr. JT, et al. for the ALLHAT Collaborative Research Group. Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 2001;22:29–41.
Collins JF, Howell CL, Horney RA, for the Digitalis Investigation Group (DIG) Investigators. Determination of vital status at the end of the DIG trial. Control Clin Trials 2003;24:726–730.
Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.
Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756–1764.
Fisher B, Redmond CK: Fraud in breast-cancer trials. N Engl J Med 1994;330:1458–1462.
Buyse M, George SL, Evans S, et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med 1999;18:3435–3451.
Sheldon T. Dutch neurologist found guilty of fraud after falsifying 438 case records. Br Med J 2002;325:734.
Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601–1604.
POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-1847 (Web attachment 1).
Rostami R, Nahm M, Pieper CF. What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997–2006. Clin Trials 2009;6:141–150.
Eisenstein EL, Lemons II PW, Tardiff BE, et al. Reducing the cost of phase III cardiovascular clinical trials. Am Heart J 2005;149:482–488.
Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008;5:75–84.
Trials Journal. http://www.trialsjournal.com.
Hrynaszkiewicz I, Altman DG. Towards agreement on best practice for publishing raw clinical trial data (Editorial). Trials 2009;10:17.
Editorial. Reporting clinical trials message and medium. Lancet 1994;344:347–348.
National Institutes of Health (NIH). Final NIH statement on sharing research data. February 26, 2003. http://grants.nih.gov/grants/policy/datasharing/.
US Department of Health and Human Services. NIH News. National Institutes of Health. NIH halts use of COX-2 inhibitor in large cancer prevention trial. December 17, 2004. http://www.nih.gov/news/pr/dec2004/od-17.htm.
Zarin DA, Ide NC, Tse T, et al. Issues in the registration of clinical trials. JAMA 2007;297:2112–2120.
Zarin DA, Tse T. Moving toward transparency of clinical trials. Science 2008;319:1340–1342.
Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878–881.
Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–447.
Meador KJ, Baker GA, Browning N, et al on behalf of the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597–1605.
Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069–1118.
The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.
Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980; ii:379–385.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JACC 1986;8:1245–1255.
Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982;248:1465–1477.
Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. JAMA 1990;263:1795–1801.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2010 Springer New York
About this chapter
Cite this chapter
Friedman, L.M., Furberg, C.D., DeMets, D.L. (2010). Closeout. In: Fundamentals of Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1586-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1586-3_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1585-6
Online ISBN: 978-1-4419-1586-3
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)